Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
The affected product is identified as Veklury lot # 47035CFA, distributed nationwide starting July 16, 2024. Gilead is notifying distributors and customers through UPS next-day air mail, instructing pharmacies to cease use of the affected lot and return any remaining vials.Gilead Sciences Inc. (NASDAQ:GILD) has voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials.
吉利德科学公司（纳斯达克：GILD）自愿召回了其COVID-19治疗药物维康利（瑞德西韦）100毫克/瓶注射剂的一个批次，因在瓶中发现玻璃颗粒。
The company received a customer complaint that prompted an investigation, confirming the presence of foreign material in the product.
公司收到了引发调查的客户投诉，确认产品中存在异物。
Also Read: Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections.
另请阅读：吉利德公布研究晚期力那卡伏试验的“显著成果”，显示在预防HIV感染方面具有潜力。
The affected product is identified as Veklury lot # 47035CFA, distributed nationwide starting July 16, 2024. Gilead is notifying distributors and customers through UPS next-day air mail, instructing pharmacies to cease use of the affected lot and return any remaining vials.
受影响的产品被确定为维康利批号# 47035CFA，从2024年7月16日开始在全国范围内分发。吉利德正在通过UPS次日空邮通知经销商和客户，指示药店停止使用受影响批次，并退回任何剩余的药瓶。
Gilead is taking necessary measures to ensure the safety of patients and healthcare providers by facilitating the recall process.
吉利德正在采取必要措施确保通过促进召回过程来保障患者和医疗服务提供者的安全。
The administration of a contaminated injectable could lead to health risks, including local irritation or swelling. If glass particles travel through the bloodstream, they may obstruct blood vessels in vital organs, potentially resulting in strokes or even death.
注射受污染的药物可能导致健康风险，包括局部刺激或肿胀。如果玻璃颗粒穿过血液循环，可能阻塞重要器官的血管，潜在导致中风甚至死亡。
Gilead has reported no adverse events associated with this recall to date.
吉利德迄今为止尚未报告与此次召回相关的任何不良事件。
Veklury is designed for the treatment of COVID-19 in both adults and pediatric patients, specifically those who are hospitalized or non-hospitalized but at high risk of progression to severe COVID-19.
维康利旨在治疗COVID-19，适用于成人和儿童患者，尤其是住院患者或非住院但有严重COVID-19进展高风险者。
Its use is restricted to healthcare settings that manage severe reactions, including anaphylaxis.
其使用仅限于管理严重反应，包括过敏性休克的医疗机构。
In 2021, Gilead Sciences issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because they contained glass particulates.
2021年，吉利德科学公司因其COVID-19治疗药物瑞德西韦的两批产品含有玻璃颗粒而发布全国召回。
In the second quarter of 2024, Veklury sales decreased 16% year over year to $214 million, primarily due to lower rates of COVID-19-related hospitalizations.
2024年第二季度，Veklury销售额同比下降16%，至2.14亿美元，主要是因COVID-19相关住院率降低。
Price Action: GILD stock is down 0.05% at $83.90 at last check Monday.
股价走势：吉利德科学股票在周一最后交易时下跌0.05%，报收83.90美元。